IMBRUVICA 140 mg, hard capsule 120 capsules
Active ingredients: Ibrutinib
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule120 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMBRUVICA 140 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 120 gélule(s)
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 25 Nov 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63012197CIP72794990CIP133400927949906Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IBRUTINIBgélule | 140 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.